Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Monotherapy in AF Patients Post-PCI
NCT06103266Phase 4Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of rivaroxaban in Atrial fibrillation (AFib), coronary artery disease (CAD). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06103266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103266.